vs
Medpace Holdings, Inc.（MEDP）与MAXCYTE, INC.（MXCT）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是MAXCYTE, INC.的148.0倍（$708.5M vs $4.8M）。Medpace Holdings, Inc.净利率更高（19.1% vs -200.5%，领先219.5%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -20.9%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-2.9M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -7.4%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
MEDP vs MXCT — 直观对比
营收规模更大
MEDP
是对方的148.0倍
$4.8M
营收增速更快
MEDP
高出53.0%
-20.9%
净利率更高
MEDP
高出219.5%
-200.5%
自由现金流更多
MEDP
多$191.0M
$-2.9M
两年增速更快
MEDP
近两年复合增速
-7.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $4.8M |
| 净利润 | $135.1M | $-9.6M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | -234.5% |
| 净利率 | 19.1% | -200.5% |
| 营收同比 | 32.0% | -20.9% |
| 净利润同比 | 15.5% | 9.4% |
| 每股收益（稀释后） | $4.65 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPMXCT
| Q4 25 | $708.5M | $4.8M | ||
| Q3 25 | $659.9M | $4.6M | ||
| Q2 25 | $603.3M | $5.8M | ||
| Q1 25 | $558.6M | $5.7M | ||
| Q4 24 | $536.6M | $6.1M | ||
| Q3 24 | $533.3M | $5.6M | ||
| Q2 24 | $528.1M | $5.0M | ||
| Q1 24 | $511.0M | $5.6M |
净利润MEDPMXCT
| Q4 25 | $135.1M | $-9.6M | ||
| Q3 25 | $111.1M | $-12.4M | ||
| Q2 25 | $90.3M | $-12.4M | ||
| Q1 25 | $114.6M | $-10.3M | ||
| Q4 24 | $117.0M | $-10.6M | ||
| Q3 24 | $96.4M | $-11.6M | ||
| Q2 24 | $88.4M | $-9.4M | ||
| Q1 24 | $102.6M | $-9.5M |
营业利润率MEDPMXCT
| Q4 25 | 21.6% | -234.5% | ||
| Q3 25 | 21.5% | -307.4% | ||
| Q2 25 | 20.9% | -244.3% | ||
| Q1 25 | 20.3% | -214.1% | ||
| Q4 24 | 23.4% | -213.1% | ||
| Q3 24 | 21.1% | -250.4% | ||
| Q2 24 | 19.9% | -241.0% | ||
| Q1 24 | 20.4% | -219.8% |
净利率MEDPMXCT
| Q4 25 | 19.1% | -200.5% | ||
| Q3 25 | 16.8% | -269.7% | ||
| Q2 25 | 15.0% | -212.2% | ||
| Q1 25 | 20.5% | -178.7% | ||
| Q4 24 | 21.8% | -175.0% | ||
| Q3 24 | 18.1% | -205.9% | ||
| Q2 24 | 16.7% | -188.8% | ||
| Q1 24 | 20.1% | -170.6% |
每股收益（稀释后）MEDPMXCT
| Q4 25 | $4.65 | — | ||
| Q3 25 | $3.86 | $-0.12 | ||
| Q2 25 | $3.10 | $-0.12 | ||
| Q1 25 | $3.67 | — | ||
| Q4 24 | $3.67 | — | ||
| Q3 24 | $3.01 | $-0.11 | ||
| Q2 24 | $2.75 | $-0.09 | ||
| Q1 24 | $3.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $103.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $171.5M |
| 总资产 | $2.0B | $202.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPMXCT
| Q4 25 | $497.0M | $103.0M | ||
| Q3 25 | $285.4M | $105.7M | ||
| Q2 25 | $46.3M | $126.6M | ||
| Q1 25 | $441.4M | $138.3M | ||
| Q4 24 | $669.4M | $154.5M | ||
| Q3 24 | $656.9M | $153.8M | ||
| Q2 24 | $510.9M | $157.3M | ||
| Q1 24 | $407.0M | $157.5M |
股东权益MEDPMXCT
| Q4 25 | $459.1M | $171.5M | ||
| Q3 25 | $293.6M | $180.3M | ||
| Q2 25 | $172.4M | $190.7M | ||
| Q1 25 | $593.6M | $199.4M | ||
| Q4 24 | $825.5M | $206.3M | ||
| Q3 24 | $881.4M | $213.3M | ||
| Q2 24 | $763.6M | $221.3M | ||
| Q1 24 | $671.5M | $226.4M |
总资产MEDPMXCT
| Q4 25 | $2.0B | $202.5M | ||
| Q3 25 | $1.8B | $213.5M | ||
| Q2 25 | $1.6B | $219.8M | ||
| Q1 25 | $1.9B | $230.0M | ||
| Q4 24 | $2.1B | $239.5M | ||
| Q3 24 | $2.1B | $248.6M | ||
| Q2 24 | $1.9B | $251.5M | ||
| Q1 24 | $1.8B | $257.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $-2.7M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $-2.9M |
| 自由现金流率自由现金流/营收 | 26.6% | -61.0% |
| 资本支出强度资本支出/营收 | 0.6% | 4.8% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $-36.2M |
8季度趋势，按日历期对齐
经营现金流MEDPMXCT
| Q4 25 | $192.7M | $-2.7M | ||
| Q3 25 | $246.2M | $-7.5M | ||
| Q2 25 | $148.5M | $-9.9M | ||
| Q1 25 | $125.8M | $-14.4M | ||
| Q4 24 | $190.7M | $-7.8M | ||
| Q3 24 | $149.1M | $-4.4M | ||
| Q2 24 | $116.4M | $-4.8M | ||
| Q1 24 | $152.7M | $-10.6M |
自由现金流MEDPMXCT
| Q4 25 | $188.1M | $-2.9M | ||
| Q3 25 | $235.5M | $-7.8M | ||
| Q2 25 | $142.4M | $-10.4M | ||
| Q1 25 | $115.8M | $-15.1M | ||
| Q4 24 | $183.0M | $-8.0M | ||
| Q3 24 | $138.5M | $-4.8M | ||
| Q2 24 | $103.5M | $-5.1M | ||
| Q1 24 | $147.2M | $-11.4M |
自由现金流率MEDPMXCT
| Q4 25 | 26.6% | -61.0% | ||
| Q3 25 | 35.7% | -168.5% | ||
| Q2 25 | 23.6% | -179.2% | ||
| Q1 25 | 20.7% | -262.3% | ||
| Q4 24 | 34.1% | -131.6% | ||
| Q3 24 | 26.0% | -85.5% | ||
| Q2 24 | 19.6% | -103.3% | ||
| Q1 24 | 28.8% | -203.6% |
资本支出强度MEDPMXCT
| Q4 25 | 0.6% | 4.8% | ||
| Q3 25 | 1.6% | 6.5% | ||
| Q2 25 | 1.0% | 10.0% | ||
| Q1 25 | 1.8% | 11.4% | ||
| Q4 24 | 1.4% | 2.4% | ||
| Q3 24 | 2.0% | 7.2% | ||
| Q2 24 | 2.4% | 5.9% | ||
| Q1 24 | 1.1% | 14.4% |
现金转化率MEDPMXCT
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
MXCT
暂无分部数据
